ALPORT SYNDROME

Alport Syndrome — a progressive kidney disease where early ACE inhibitor therapy delays kidney failure by 10-18 years, but only if the diagnosis is made before proteinuria develops.

Whole genome sequencing evaluates all three Alport genes — COL4A3, COL4A4, and COL4A5 — identifying the specific variant and inheritance pattern that determines renal prognosis and the urgency of nephroprotective therapy.

COL4A5
COL4A3
COL4A4

About this condition

Alport Syndrome

Alport syndrome is a hereditary nephropathy caused by pathogenic variants in genes encoding type IV collagen — the major structural component of basement membranes in the kidney glomerulus, inner ear, and eye. Three genes are involved: COL4A5 (X-linked, ~80% of cases), COL4A3 (autosomal), and COL4A4 (autosomal). X-linked Alport syndrome is the most common and most severe form: affected males develop progressive hematuria, proteinuria, sensorineural hearing loss, anterior lenticonus, and end-stage renal disease typically by age 25-30 without treatment.

The critical advance in Alport management is that ACE inhibitor therapy — started before proteinuria develops, in patients with isolated hematuria — delays ESRD by approximately 10-18 years. This represents one of the most dramatic examples of genotype-guided preventive therapy in nephrology. However, the benefit depends entirely on early identification: by the time proteinuria develops, significant glomerular damage has already occurred. Most Alport patients are still diagnosed late.

Female carriers of X-linked Alport syndrome were historically described as 'unaffected carriers,' but approximately 30-40% develop proteinuria, 15-30% develop hearing loss, and 12-15% progress to ESRD by age 60. Autosomal recessive Alport syndrome (COL4A3/COL4A4 biallelic variants) produces a similar phenotype in both sexes. Heterozygous COL4A3/COL4A4 carriers may present as 'thin basement membrane nephropathy' — now recognized as a spectrum that includes some carriers who progress to CKD.

Female carriers of X-linked Alport syndrome are frequently symptomatic — approximately 15% reach end-stage renal disease by age 60.

Gene locus: COL4A5 (Xq22.3), COL4A3 (2q36.3), COL4A4 (2q36.3)

Molecular testing has replaced kidney biopsy as the first-line diagnostic approach for suspected Alport syndrome — less invasive and more informative for genetic counseling.

ACE inhibitors delay kidney failure by 10-18 years — but only if started before proteinuria, requiring early genetic diagnosis

The European Alport Therapy Registry demonstrated that ACE inhibitor therapy initiated during the hematuria-only stage delayed ESRD by a median of 18 years in males with X-linked Alport syndrome. Without molecular diagnosis, most patients receive ACEi therapy only after proteinuria is established. Whole genome sequencing in a child with persistent hematuria can establish the Alport diagnosis and trigger early ACEi initiation during the optimal treatment window.

Thin basement membrane nephropathy is not always benign — COL4A3/A4 heterozygotes can progress to CKD

Thin basement membrane nephropathy was historically considered benign. It is now recognized that approximately 15-20% of COL4A3/A4 heterozygotes develop meaningful proteinuria or CKD by middle age. Molecular diagnosis reclassifies 'benign TBMN' as carrier Alport status, warranting longitudinal renal monitoring and appropriate genetic counseling for family members.

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test